Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study
ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.
Pharma & Biotech
Pharma & Biotech
Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.